Smith, Hannah L. http://orcid.org/0000-0001-6231-1486
Willmore, Elaine
Prendergast, Lisa
Curtin, Nicola J. http://orcid.org/0000-0003-1369-1843
Article History
Received: 3 August 2023
Revised: 24 May 2024
Accepted: 31 May 2024
First Online: 4 July 2024
Competing interests
: N.J.C. contributed to the development of rucaparib and obtained research funding from Agouron Pharmaceutical, Pfizer, and Clovis. By virtue of the two active patents and an original agreement between Cancer Research Technology, Newcastle University, and Agouron, she is in receipt of royalty payments, which she does not take personally.
: Malignant ascites were collected from patients with ovarian cancer undergoing surgery or palliative drainage of ascites at the Queen Elizabeth Hospital, Gateshead, UK. Ethical approval and informed written consent was attained from North East Newcastle and North Tyneside 1 Research Ethics Committee for the collection of both clinical material and patient data. Samples were handled in accordance with the Human Tissue Act (2004).